Research ArticleOpen AccessGoogle Scholar indexed
Research Progress of Jianpi Qushi Powder Combined with Standard Anti Hp Quadruple Therapy in the Treatment of Hp Infectious Gastritis with Spleen Deficiency and Dampness Stagnation
Guigang Orthopedic Hospital of Integrated Traditional Chinese and Western Medicine, Guigang, China
Guigang Skin Disease Prevention and Treatment Hospital, Guigang, China
People’s Hospital of Guangxi ASEAN Economic and Technological Development Zone/Nanning Tenth People’s Hospital, Nanning, China
People’s Hospital of Guangxi ASEAN Economic and Technological Development Zone/Nanning Tenth People’s Hospital, Nanning, China
- 1 Guigang Orthopedic Hospital of Integrated Traditional Chinese and Western Medicine, Guigang, China
- 2 Guigang Skin Disease Prevention and Treatment Hospital, Guigang, China
- 3 People’s Hospital of Guangxi ASEAN Economic and Technological Development Zone/Nanning Tenth People’s Hospital, Nanning, China
- 4 People’s Hospital of Guangxi ASEAN Economic and Technological Development Zone/Nanning Tenth People’s Hospital, Nanning, China
Copy link · social · email
Abstract
Stomach Helicobacter pylori infection is one of the common gastric diseases. Helicobacter pylori infectious gastritis of spleen deficiency and dampness stagnation is a relatively intractable chronic disease. In recent years, traditional Chinese medicine methods have emerged one after another in the treatment of gastric Helicobacter pylori infection. By collecting references, the author reviewed the clinical characteristics of gastric Helicobacter pylori infection and the new progress of traditional Chinese medicine treatment.
KeywordsTraditional Chinese Medicine Jianpi Qushi PowderQuadruple TherapySpleen Deficiency Dampness Stagnation Type<i>Helicobacter Pylori</i>InfectionGastritis
- Kimura, K., Taniguchi, Y., Satoh, K., et al. (1997) Composition for the Treatment of Helicobacter pylori Infection. Kaken Pharmaceutical Co Ltd., US5618564A.
- Technische Universität München and Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V. (2017) Helicobacter pylori Vaccines. World Patent Organization, WO2017102779A1.
- Abadi, A. (2015) Helicobacter pylori and Gastric Cancer: Clinical Aspects. Chinese Journal of Medicine (English Version), 128, 3101-3105. https://doi.org/10.4103/0366-6999.169107
- Yang, J.C., Shun, C.T., Chien, C.T. and Wang T.H. (2010) Composition for the Prevention and the Treatment of Helicobacter pylori Infection. National Taiwan University, US2010298244A1.
- Shiota, S. and Yamaoka, Y. (2014) Strategy for the Treatment of Helicobacter pylori Infection. Current Pharmaceutical Design, 20, 4489-4500.
- Garault, P., Bourdet-Sicard, R. and Megraud, F. (2014) Streptococcus thermophilus Strains for Treating Helicobacter pylori Infection. World Patent Organization, WO2014064488A1.
- SHIONOGI & Co Ltd. (2000) Vaccine Composition for Infection of Helicobacter pylori. Shionogi & Co Ltd., JP2000083671.
- Harris, A. (2001) Treatment of Helicobacter pylori. World Journal of Gastroenterology, 7, 303-307.
- CHIRON Corporation. (1998) Helicobacter pylori Diagnostics. Chiron Corporation, CA2270163A1.
- Jonsson, A.B. and Wehelie, R. (2011) Compounds, Medicaments and Methods of Treatment for Helicobacter pylori Infection. World Patent Organization, WO2011139226A1.
- Jonsson, A.B. and Wehelie, R. (2013) Compounds, Medicaments and Methods of Treatment for Helicobacter pylori Infection. European Patent Office, EP2566498A1.
- Go, M.F. and Fennerty, M.B. (1998) Treatment of Helicobacter pylori Infection. Current Opinion in Gastroenterology, 14, 64-69.
- Coton, T., Debonne, J.M., Guisset, M., et al. (1997) L’infection a Helicobacter pylori dans les pays en developpement. Medecine Tropicale, 57, 77-82.
- Lin, C.H. and Liu, T.W. (2014) Compositions and Assays for Treatment and Diagnosis of Helicobacter pylori Infection and Conditions. US8785402B2.
- Chey, W.D., Leontiadis, G.I., Howden, C.W., et al. (2017) ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. The American Journal of Gastroenterology, 112, 212-239.